Skip to main content

Table 3 Hazard ratios of established prognostic parameters and PSCA expression in prostate cancer

From: PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer

Scenario

1

2

3

4

Analyzable (N)

8334

8454

8570

5801

Gleason grade biopsy

    

 3 + 4 vs. ≤3 + 3

1.94***

   

 4 + 3 vs. 3 + 4

1.63***

   

 ≥4 + 4 vs. 4 + 3

1.39***

   

cT stage

    

 T2a vs. T1c

1.53***

1.47***

  

 T3a vs. T2c

0.65*

1.07

  

Preoperative PSA level

    

 4–10 vs. < 4

1.25*

1.21*

1.11

1.14

 10–20 vs. 4–10

1.58***

1.41***

1.25***

1.16*

 > 20 vs. 10–20

1.67***

1.47***

1.23*

1.22*

PSCA expression

    

 Positive vs. negative

0.84***

0.86**

0.93

0.93

Gleason grade prostatectomy

    

 3 + 4 vs. ≤3 + 3

 

2.91***

2.39***

2.30***

 4 + 3 vs. 3 + 4

 

2.72***

2.24***

2.05***

 ≥4 + 4 vs. 4 + 3

 

1.75***

1.25*

1.21*

pT stage

    

 T3a vs. T2

  

1.94***

1.94***

 T3b vs. T3a

  

1.73***

1.52***

 T4 vs. T3b

  

1.20

1.24

Surgical margin (R) status

    

 R1 vs. R0

  

1.40***

1.18*

 Nodal (pN) stage

    

 N+ vs. N0

   

1.56***

  1. Scenario 1 combines preoperatively available parameter (preoperative Gleason grade obtained on the original biopsy, clinical tumor (cT) stage, and preoperative PSA) with the postoperative PSCA expression. In scenario 2 the biopsy Gleason is replaced by the Gleason grade obtained on radical prostatectomy. In scenario 3 cT stage is superseded by pathological tumor (pT) stage and surgical margin (R) status. In scenario 4 the lymph node (pN) stage is added. Asterisk indicate significance level: * p ≤ 0.05, ** p ≤ 0.001, and *** p ≤ 0.0001